Context: Elevated blood glucose levels occur frequently in the critically ill. Tight glucose control by intensive insulin treatment markedly improves clinical outcome.
Results: Mean blood glucose was 6.2 Ϯ 1.1 mmol/liter in the eMPC vs. 7.2 Ϯ 1.1 mmol/liter in the RMP group (P Ͻ 0.05); percentage of time in the target range was 60.4 Ϯ 22.8% for the eMPC vs. 27.5 Ϯ 16.2% for the RMP group (P Ͻ 0.05). No severe hypoglycemia (blood glucose Ͻ 2.9 mmol/liter) occurred during the study. Mean insulin infusion rate was 4.7 Ϯ 3.3 IU/h in the eMPC vs. 2.6 Ϯ 1.7 IU/h in the RMP group (P Ͻ 0.05). Mean sampling interval was 1.5 Ϯ 0.3 h in the eMPC vs. 2.1 Ϯ 0.2 h in the RMP group (P Ͻ 0.05). E LEVATED BLOOD GLUCOSE levels are commonly observed in the critically ill (1) (2) (3) . This phenomenon denoted "diabetes of injury" presents indiscriminately in diabetic and nondiabetic critically ill patients, and has distinct pathophysiology from type 1 or 2 diabetes (4). The main cause of hyperglycemia in the critically ill is the release of counterregulatory stress hormones (catecholamines, cortisol, glucagon, GH) and proinflammatory cytokines that interfere with the insulin signaling cascade at the postreceptor level (5, 6) . Hyperglycemia in critically ill patients has many undesirable effects, such as increased oxidative stress (7) (8) (9) , increased infectious complications (10) , impaired cardiovascular function (11, 12) , prothrombogenic effect, endothelial dysfunction (13) (14) (15) , ischemic renal injury, and others (16) .
Conclusions
Numerous clinical studies have demonstrated that tight glycemic control by intensive insulin therapy improves clinical outcome by decreasing the risk of complications in critically ill patients (17) . In a prospective randomized trial in Leuven, post-cardiac surgery patients were treated either by a conventional or intensive insulin regimen (18) . Tight glucose control (4.4 -6.1 mmol/liter) reduced in-hospital mortality and decreased organ system dysfunction compared with the conventional group that had moderate hyperglycemia (6.1-11.1 mmol/liter). In a mixed adult medicalsurgical population, the implementation of an intensive glucose management protocol decreased mortality, morbidity, and the length of intensive care unit (ICU) stay (19) . Another study performed in Leuven at the medical ICU failed to show significant influence of glucose control on overall mortality. However, morbidity was significantly reduced by the prevention of newly acquired kidney injury, accelerated weaning from the mechanical ventilation, and accelerated discharge from the ICU and hospital (20) .
Large-scale clinical studies together with other indicative data demonstrated tight glucose control to be an important prerequisite of improved survival and reduced morbidity in the critically ill. However, tight glucose control is not easy to achieve. It is based on the combination of a continuous iv insulin infusion and frequent blood glucose measurements, potentially increasing the workload of the nursing staff. Importantly, tight glucose control significantly increases the risk of hypoglycemia, potentially harming the patients. Therefore, the implementation of tight glucose control in the ICU requires not only safe and efficacious glucose management protocols but also appropriate education of health care professionals.
Numerous glucose management protocols have been developed to achieve tight glycemic control, including computer-based algorithms (21) (22) (23) (24) (25) 
Subjects and Methods

Study design and subjects
The study was designed as a single-center nonblinded randomized trial. A total of 60 adult patients [43 men and 17 women; mean age 68 Ϯ 10 yr; mean body mass index (BMI) 27.2 Ϯ 4.6 kg/m 2 ; 27 patients with type 2 diabetes mellitus) admitted for major elective cardiac surgery (51 patients with aortocoronary bypass, nine with valvular plastic) participated in the study. There were 30 patients randomized for treatment by the computer algorithm with variable sampling (eMPC) and 30 using the standard glucose management protocol developed at the Department of Cardiovascular Surgery, General University Hospital, Prague (Fig. 1) . A total of 13 patients from the eMPC and 14 from the standard protocol group had a history of diabetes; on admission, six of 13 patients in the eMPC group and seven of 14 patients in the standard group were treated by peroral antidiabetic drugs (glimepiride, metformin, or both). The remaining patients with diabetes were treated by insulin.
The mean duration of the surgery was 5.6 Ϯ 1.3 h. Characteristics of both groups are shown in Table 1 .
The study consisted of two parts: a screening visit performed 1 d before the surgery, and a treatment visit that coincided with the start of surgery and continued for up to 24 h at the ICU. A written informed consent was signed by all participants before being enrolled in the study. Keep the same rate, if glycemia is stable in the 2 following measurements, the next glucose level could be checked in 4 hours 2 hour 6.0 -6.9 Increase rate by 0,5 ml/h 2 hour 7.0 -7.9
Increase rate by 1 ml/h 2 hour 8.0 -9.9
Increase rate by 2 ml/h 2 hour 10.0 -12.9 Bolus 5 IU, increase rate by 3 ml/h 1 hour 13.0 -15. Republic, and was performed in accordance with the guidelines proposed in the Declaration of Helsinki. Exclusion criteria were defined as: insulin allergy, mental incapacity, and language barrier.
Patients' examination and blood sampling
An anthropometric examination of the patients was part of the screening visit performed 1 d before the surgery. All subjects were measured and weighted, and BMI was calculated. A blood sample was taken for routine laboratory examination. Diabetes history, and information about concomitant illnesses and medication were collected.
During the treatment part of the study, the blood samples were withdrawn from the arterial line and measured on an ABL 700 analyzer (Radiometer Medical A/S, Copenhagen, Denmark). The first sample was taken before the start of the surgery (time 0). Patients were randomized to the eMPC or standard protocol treatment, regardless of the preoperative blood glucose level. No threshold glucose level was defined as an inclusion criterion.
Subsequent samples were taken as requested by the eMPC or standard protocol. The insulin treatment started at the beginning of the surgery and continued until the end of the study. In the eMPC group, the insulin infusion started based on the advice of the eMPC; in the standard protocol group, insulin administration started when blood glucose was more than 9 mmol/liter. Insulin was given iv through a central venous catheter using a 50-ml syringe and standard infusion pumps. The standard concentration was 50 IU Actrapid HM (Novo Nordisk, Baegsvard, Denmark) in 50 ml 0.9% NaCl. A continuous iv infusion of 10% glucose solution was administered during whole study in all patients (5-7 g/h according to an institutional protocol). No additional nutrition was administered.
MPC and routine glucose management protocol
The eMPC algorithm used in this study has been described in detail previously (27, 28) . Briefly, the eMPC includes a model of the glucoregulatory system. The model adapts itself to the input-output relationship observed during tight glucose control, i.e. an incoming glucose measurement is used by the model to update model parameters such as insulin sensitivity, considering previously given insulin, and parenteral and enteral glucose. Compared with the original MPC controller developed for the treatment of type 1 diabetes and using sc insulin delivery (27, 28) , the eMPC for the treatment of the critically ill is simplified because insulin is delivered iv, and a submodel describing insulin absorption from the sc depot is not needed. However, the higher intersubject and temporal variability in insulin sensitivity and insulin needs among the critically ill compared with subjects with type 1 diabetes makes the delivery of an appropriate insulin dose challenging.
Once individualized to a critically ill subject, the eMPC uses the glucoregulatory model to determine the optimum insulin infusion rate that is expected achieve the target glucose concentration. This is achieved by numerical optimization using simulated experiments with the individualized glucoregulatory model. The output of this optimization is a sequence of insulin infusion rates that are expected, based on model predictions, to result in the target glucose concentration over a period of 4 h. The first insulin infusion rate is displayed to the user and recommended for the delivery.
The determination of the time-to-next glucose sample uses prediction accuracy. Through an internal procedure, the eMPC estimates how accurately it is able to predict glucose concentration. The extent of accuracy will differ over time because the unexplained variability in glucose concentration varies due to, for example, temporal variations in insulin sensitivity. The estimated prediction accuracy is used by the eMPC to plot a prediction envelope. This is a funnel-like prediction shape indicating a range of possible glucose concentrations at each time point in the future. Once the prediction funnel crosses a border indicating nonacceptable bounds, this might be a level indicating a risk of hypoglycemia or unacceptable hyperglycemia, the eMPC suggests a sample to be taken.
Glucose concentration, insulin dosage, and carbohydrate intake are the input variables for the eMPC. The insulin infusion rate and the time of the next glucose sample are the outputs. The eMPC was implemented on a laptop computer.
The target range for blood glucose levels, as defined by the study protocol, was 4.4 -6.1 mmol/liter, which has reduced mortality and morbidity in post-cardiac surgery patients (18) . The percentage of time in the target range was calculated as the number of values in the target range in each patient divided by the number of measurements multiplied by 100.
The standard algorithm is described in detail in Fig. 1 . Severe hypoglycemia was defined as blood glucose less than 2.9 mmol/liter.
Statistical analysis
The statistical analysis was performed using SigmaStat (Jandel Scientific, San Rafael, CA). The results are expressed as mean Ϯ sd. Differences between the standard and eMPC groups were evaluated using the t test or Mann-Whitney U rank sum test as appropriate. Table 1 shows characteristics of the standard glucose management protocol and eMPC groups. The groups did not significantly differ with respect to age, BMI, duration of surgery, number of patients with previously diagnosed diabetes, or baseline blood glucose.
Results
Blood glucose control characteristics, blood glucose and insulin infusion rate profiles, and percentage time in predefined ranges of both groups are shown in Tables 2 and 3 , and Figs. 2 and 3, respectively. Mean blood glucose throughout the entire study, at the operating theater, and at the ICU was significantly lower in the eMPC vs. standard glucose management protocol group (Table 2) . On the contrary, the mean insulin infusion rate and the total insulin dose were significantly higher in the eMPC vs. standard glucose management protocol group. The mean sampling interval was significantly shorter in the eMPC vs. standard glucose management protocol group ( Table 2) .
The percentage time in the target range (4.4 -6.1 mmol/ liter) and less than the target range was significantly higher in the eMPC vs. standard glucose management protocol Unless stated otherwise, values are the mean Ϯ SD. No significant differences between the groups were found among parameters.
TABLE 2.
The mean blood glucose, insulin infusion rate, total insulin dose, and sampling interval during the entire study, at the operating theater, and at the ICU in patients treated by the standard glucose management protocol or the eMPC algorithm (mean Ϯ SD) Table 3 ). The percentage time more than the target range was significantly lower in the eMPC vs. standard glucose management protocol group. No severe hypoglycemia defined as blood glucose lower than 2.9 mmol/liter was observed during the study.
Hourly profiles of mean blood glucose values and insulin infusion rates are displayed in Figs. 2 and 3 , respectively.
Discussion
The present study demonstrates that a laptop-based eMPC algorithm can safely and effectively control blood glucose levels in patients during and after elective cardiac surgery.
A major limitation of the previous version of the MPC was the need for hourly blood glucose measurements (29) . It was argued that frequent blood sampling may have biased the overall results toward the eMPC relative to the standard protocol. Furthermore, hourly blood glucose sampling puts an additional burden on the nursing staff because it is more frequent than that prescribed by standard treatment protocols in most ICUs and is difficult to achieve under outsidestudy conditions. To address this criticism, we modified the MPC sampling pattern to allow a less frequent blood glucose sampling. The eMPC evaluates how well it can predict glucose excursions and increases the sampling interval once its predictions have become more accurate. This usually means that a more frequent sampling pattern is established during highly dynamic conditions such as during the surgery or the early part of a stay at the ICU when postoperative stress and treatment procedures may induce considerable variability in insulin sensitivity and, thus, limit the ability of the MPC to make accurate predictions of glucose excursions. Using information about the prediction accuracy, the mean sampling interval in the eMPC group increased from hourly to 1.5 Ϯ 0.3 h, which was still significantly more frequent than in the standard glucose management protocol group (1.5 Ϯ 0.3 h in the eMPC vs. 2.1 Ϯ 0.2 h in the standard group; P Ͻ 0.05). Compared with our earlier report (26) , the present study used the eMPC during and after the surgery, used a 10% dextrose infusion in both treatment groups, and adopted a single-center study design.
The additional modifications of the eMPC algorithm resulted in establishing a tighter glucose control compared with the original version with hourly blood glucose sampling. The original MPC gave a mean blood glucose level of 6.5 Ϯ 0.1 mmol/liter and the percentage of time in the target range of 54.8 Ϯ 8.8% (26) . The present eMPC resulted in the mean blood glucose level of 6.2 Ϯ 1.1 mmol/liter and the percentage in the target range of 60.4 Ϯ 22.8%. The new eMPC algorithm was also more effective in establishing the target blood glucose range. The time-to-target was 10.3 Ϯ 0.9 h using the original MPC vs. 6.5 Ϯ 4.1 h with the currently tested eMPC.
Another important finding of the present study was that both the standard glucose management protocol and the eMPC were safe with respect to the incidence of severe hypoglycemia. No severe hypoglycemia occurred in the eMPC or standard glucose management protocol group. The fear of hypoglycemia represents a major barrier for the implementation of tight glucose control in ICUs. The benefit vs. harm analysis balancing the tight glucose control against the danger of complications of hypoglycemia is a hotly discussed topic in the critical care community (30) .
In conclusion, our study demonstrated that a computer algorithm with variable sampling (eMPC) was more effective in achieving tight glucose control in post-cardiac surgery patients than the standard protocol. The use of the algorithm on a laptop or its implementation in a stand-alone infusion system promises the achievement of tight glucose control in the critically ill.
